Combo study of Gilead antiviral, Lilly anti-inflammatory drug positive in Covid-19, but raises pricing jitters

An analyst wrote Wednesday that the combination of Lilly's Olumiant and Gilead's Veklury, or remdesivir, could cost nearly $8,000, a high price tag that could potentially hamper uptake, especially given the availability of cheaper drugs like dexamethasone.